RE:RE:RE:RE:RE:RE:RE:RE:Master plan news coming I feel it The currency of WELL is not super weak, as the company has issued shares to institutional investors and insiders at great premiums to market trading prices on several occasions. It can do so again. In case you haven't noticed, it's been issuing shares at $9.80 to acquisition targets, insiders and institutional investors, much higher than then market prices.
A few years of negative EPS, and negative EPS, doesn't mean anything. Earnings are not the way to valuate a growth by capital allocation company, at least not yet.
Why do you think dilution is a bad thing without considering accretion? If the issuance of shares to partially fund a transaction is accretive, then such issuance "dilution" is just fine.
WELL is the holdco behind a basket of digital and clinical health assets. There is no reason to sell itself when it can achieve higher growth through its proven capital allocation strategy.